Northwest Biotherapeutics, Inc. Common stock
NWBO
NWBO was delisted on the 16th of December, 2016.
6 hedge funds and large institutions have $36K invested in Northwest Biotherapeutics, Inc. Common stock in 2020 Q1 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.
80% more capital invested
Capital invested by funds: $20K → $36K (+$16K)
50% more funds holding
Funds holding: 4 → 6 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
+$16K |
| 2 |
MSAM
Moloney Securities Asset Management
Manchester,
Missouri
|
+$5K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Victory Capital Management
San Antonio,
Texas
| $16K | +$16K | +101,003 | New |
|
|
WJWM
2
Williams Jones Wealth Management
New York
| $8K | – | – | – |
|
|
MSAM
3
Moloney Securities Asset Management
Manchester,
Missouri
| $5K | +$5K | +31,000 | New |
|
|
LDB
4
Lee, Danner & Bass
Nashville,
Tennessee
| $3K | – | – | – |
|
|
MPI
5
Mairs & Power Inc
St Paul,
Minnesota
| $2K | – | – | – |
|
|
OCG
6
Opus Capital Group
Cincinnati,
Ohio
| $2K | – | – | – |
|
NWBO Hedge Fund Activity: Q1 2020 in Review
6 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. Common stock (NWBO) for Q1 2020, worth a combined $36K — up 80% from $20K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new NWBO positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Victory Capital Management, opening a new position worth an estimated $16K.
- 6 institutional investors held Northwest Biotherapeutics, Inc. Common stock (NWBO) as of Q1 2020, up from 4 in Q4 2019.
- Funds reported $36K of Northwest Biotherapeutics, Inc. Common stock stock for Q1 2020, up 80% quarter-over-quarter.
- 2 funds opened new Northwest Biotherapeutics, Inc. Common stock positions in Q1 2020 and 0 closed out, a net change of +2 holders.
- The largest Northwest Biotherapeutics, Inc. Common stock buyer in Q1 2020 was Victory Capital Management, an estimated $16K added.
Based on aggregated 13F filings for Q1 2020.